1036 / 1084
Survival gain by Trastuzumab in HER2-positive stage IV gastric cancer:
the ToGA trial
Bang et al. Lancet 2010
•
Therapeutically relevant HER2 positivity: ~ 16%
•
Trastuzumab in HER2-positive stage IV gastric cancer:
Survival 16.0 vs. 11.8 months (HR=0.65; 95% CI 0.51-0.83)